WuXi Biologics
Shanghai, CN · Wuxi, CN
Program data pending ClinicalTrials.gov matching
· Last scored 2026-03-15
65.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (13)
Quick Facts: WuXi Biologics
- Signal Score
- 65.5/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- Shanghai, CN · Wuxi, CN
- Modalities
- CAR-T, Cell Therapy, AAV
- Active CGT Programs
- No ClinicalTrials.gov matches confirmed — 5 partnership announcements in press
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 5 partnership announcements found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy, AAV
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Partnership Announcements (from press monitoring)
Financial Stability
68.0
Parent company: WuXi AppTec
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of WuXi AppTec
SEC FilingsParent: WuXi AppTec
Parent company: WuXi AppTec
Financial assessment: 68.0/100
Capacity
63.0
2 CGT manufacturing sites
Strong partnership activity (5 articles)
Sites: Shanghai, CN, Wuxi, CN
Source: SEC EDGAR, press monitoring, company profiles
2 CGT manufacturing sites
Recent Press13 articles
2 CGT manufacturing sites
Strong partnership activity (5 articles)
Recent News 13 articles
Biologics Contract Manufacturing Market (2025) | Biopharma - openPR.com
Biologics Contract Manufacturing Market (2025) | Biopharma openPR.com
WuXi Biologics Awards Win And Earendil Deal Viewed Against Valuation - Yahoo Finance
WuXi Biologics Awards Win And Earendil Deal Viewed Against Valuation Yahoo Finance
WuXi Biologics Awards And Earendil Deal Shape Biologics Valuation Story - simplywall.st
WuXi Biologics Awards And Earendil Deal Shape Biologics Valuation Story simplywall.st
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation - PR Newswire
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation PR Newswire
WuXi Biologics Should See Expanding Pipeline and Backlog Despite Geopolitical Risk - Morningstar
WuXi Biologics Should See Expanding Pipeline and Backlog Despite Geopolitical Risk Morningstar
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation - Barchart.com
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation Barchart
Earendil Labs and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific/Multispecific Antibodies and ADCs - Yahoo Finance
Earendil Labs and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific/Multispecific Antibodies and ADCs Yahoo Finance
Sandoz reorg ahead of 'golden decade' for biosimilars; Sanofi to shed Latin America generics business - Endpoints News
Sandoz reorg ahead of 'golden decade' for biosimilars; Sanofi to shed Latin America generics business Endpoints News
Earendil Labs and WuXi Biologics Partner to Accelerate Bispecific and Multispecific Antibody Development - National Today
Earendil Labs and WuXi Biologics Partner to Accelerate Bispecific and Multispecific Antibody Development National Today
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year - PR Newswire
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year PR Newswire
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year - Space Daily
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year Space Daily
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year - Yahoo Finance
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year Yahoo Finance
Accelerating GMP Quality Control with Mass Photometry from Development to Release - Genetic Engineering and Biotechnology News
Accelerating GMP Quality Control with Mass Photometry from Development to Release Genetic Engineering and Biotechnology News
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: